Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, pledged USD 5 million to advance access to quality healthcare services for ...

Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

Boehringer Ingelheim and Circle Pharma have entered a new research partnership and licence agreement to develop a new ...

By Noah Weiland and Rebecca Robbins Hikma said it had reduced the cash portion of the offer as Boehringer Ingelheim’s generic drugs business in the U.S. had lower-than-expected sales.

Hosted by Boehringer Ingelheim, the ‘CRM Summit’, an expert engagement forum, and the ‘IMETA CRM Discussions for EXperts ...

Boehringer Ingelheim is one of the world’s leading research-oriented pharmaceutical companies. The clinical pipeline is constantly being further developed, and Boehringer Ingelheim expects new ...

A while back, pharmaphorum web editor Nicole Raleigh spoke with Daniel Schwenk, senior principal clinical data manager at Boehringer Ingelheim, and Andrea Kloeble, Product Owner, Boehringer ...

Boehringer Ingelheim and Circle Pharma Announce New Research Collaboration to Develop a Novel Precision Cancer Treatment ...

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare servic ...